Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

The agency made multiple decisions regarding coverage for diagnostic and laboratory testing that have affected the industry.

Consolidation within the industry also remained brisk as cost and reimbursement concerns provided acquisition opportunities for large national outfits.

The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.

The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.

Labcorp will acquire portions of the lab's clinical and women's health testing businesses, while MAWD will continue to provide anatomic and other pathology services.

Samples for the validation will be collected at the Catholic University of Korea and will represent people across all stages of Alzheimer's disease.

Under the agreement, Labcorp will manage Graves Gilbert's main full-service laboratory in Bowling Green, Kentucky and its facility in Glasgow, Kentucky.

The deal for shares and cash is expected to close in the first half of 2025, and Sonic expects that it will be immediately accretive to earnings per share.

Last week, readers were most interested in a story about Gates Foundation awards to Detact Diagnostics to further develop a POC system and assays to detect infectious diseases.

Analyst Doug Schenkel said that Tempus has a broad and growing menu and Twist Bio has developed a novel DNA synthesis platform. He set $60 price targets for those companies.